Hereditary diffuse gastric cancer: updated clinical practice guidelines.

Autor:	Blair VR; Department of Surgery, University of Auckland, Auckland, New Zealand; St Marks Breast Centre, Auckland, New Zealand., McLeod M; Kimihauora Health and Research Clinic, Mt Maunganui, New Zealand., Carneiro F; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Coit DG; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, NY, USA., D'Addario JL; HereditaryDiffuseGastricCancer.org, Madison, WI, USA., van Dieren JM; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Harris KL; Brisbane, QLD, Australia., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Centre, Nijmegen, Netherlands., Oliveira C; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., van der Post RS; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands., Arnold J; New Zealand Familial Gastrointestinal Cancer Service, Auckland Hospital, Auckland, New Zealand., Benusiglio PR; Consultation d'Oncogénétique, Unité Fonctionnelle d'Oncogénétique, Département de Génétique, DMU BioGeM, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France., Bisseling TM; Department of Gastroenterology, Radboud University Medical Centre, Nijmegen, Netherlands., Boussioutas A; Department of Medicine, Royal Melbourne Hospital and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Cats A; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Charlton A; Department of Histopathology, Auckland Hospital, Auckland, New Zealand., Schreiber KEC; HereditaryDiffuseGastricCancer.org, Madison, WI, USA., Davis JL; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pietro MD; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK., Fitzgerald RC; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK., Ford JM; Division of Oncology, Departments of Medicine and Genetics, Stanford University School of Medicine, Stanford, CA, USA., Gamet K; Genetic Health Service New Zealand Northern Hub, Auckland Hospital, Auckland, New Zealand., Gullo I; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Hardwick RH; Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK., Huntsman DG; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Kaurah P; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; Hereditary Cancer Program, British Columbia Cancer, Vancouver, BC, Canada., Kupfer SS; Section of Gastroenterology, Nutrition and Hepatology, University of Chicago, Chicago, IL, USA., Latchford A; St Mark's Hospital, London, UK; Department of Cancer and Surgery, Imperial College, London, UK., Mansfield PF; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nakajima T; Department of Clinical Genetic Oncology, Cancer Institute Hospital, Tokyo, Japan., Parry S; New Zealand Familial Gastrointestinal Cancer Service, Auckland Hospital, Auckland, New Zealand., Rossaak J; Department of Surgery, Tauranga Hospital, Tauranga, New Zealand., Sugimura H; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan., Svrcek M; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Department of Pathology, Hôpital Saint-Antoine, Paris, France., Tischkowitz M; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Ushijima T; Division of Epigenomics, National Cancer Centre Research Institute, Tokyo, Japan., Yamada H; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan., Yang HK; Seoul National University Hospital, Seoul, South Korea., Claydon A; Department of Gastroenterology, Tauranga Hospital, Tauranga, New Zealand., Figueiredo J; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Paringatai K; Te Tumu School of Māori, Pacific and Indigenous Studies, University of Otago, Dunedin, New Zealand., Seruca R; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Bougen-Zhukov N; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Brew T; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Busija S; No Stomach for Cancer, Madison, WI, USA., Carneiro P; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., DeGregorio L; DeGregorio Family Foundation, New York, NY, USA., Fisher H; Brisbane, QLD, Australia., Gardner E; Kimihauora Health and Research Clinic, Mt Maunganui, New Zealand., Godwin TD; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Holm KN; Department of Biochemistry and Molecular Medicine, University of California Davis School Of Medicine, Davis, CA, USA., Humar B; Laboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Centre, Department of Surgery, University Hospital Zürich, Zurich, Switzerland., Lintott CJ; Genetic Health Service New Zealand South Island Hub, Christchurch Hospital, Christchurch, New Zealand., Monroe EC; DeGregorio Family Foundation, New York, NY, USA., Muller MD; Mt Maunganui, New Zealand., Norero E; Esophagogastric Surgery Unit, Digestive Surgery Department, Hospital Dr Sotero del Rio, Pontificia Universidad Catolica de Chile, Santiago, Chile., Nouri Y; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Paredes J; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Sanches JM; Institute for Systems and Robotics, Instituto Superior Técnico, Lisbon, Portugal., Schulpen E; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Ribeiro AS; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal., Sporle A; Healthier Lives National Science Challenge, University of Otago, Dunedin, New Zealand., Whitworth J; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Zhang L; Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Reeve AE; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand., Guilford P; Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand. Electronic address: parry.guilford@otago.ac.nz.
Jazyk:	angličtina
Zdroj:	The Lancet. Oncology [Lancet Oncol] 2020 Aug; Vol. 21 (8), pp. e386-e397.
DOI:	10.1016/S1470-2045(20)30219-9
Abstrakt:	Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined. (Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu